View : 20 Download: 0
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
- A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
- Kim, Min Kyoung; Kim, Kihyun; Min, Chang-Ki; Kwak, Jae-Yong; Bae, Sang-Byung; Yoon, Sung-Soo; Lee, Je-Jung; Kim, Ki Hwan; Nam, Seung-Hyun; Mun, Yeung-Chul; Kim, Hyo Jung; Bae, Sung Hwa; Shin, Ho-Jin; Lee, Jung-Hee; Park, Joon Seong; Jeong, Seong Hyun; Lee, Mark Hong; Kim, Yang-Soo; Lee, Ho Sup; Park, Keon Woo; Lee, Won-Sik; Lee, Sang Min; Lee, Jeong-Ok; Hyun, Myung Soo; Jo, Deog Yeon; Lim, Sung-Nam; Lee, Jae Hoon; Cho, Do-Yeun; Do, Young Rok; Kim, Jeong-A; Park, Seong Kyu; Kim, Jin Seok; Kim, Soo-Jeong; Kim, Hawk; Yi, Hyeon Gyu; Moon, Joon Ho; Choi, Chul Won; Kim, Sung-Hyun; Joo, Young-Don; Kim, Hoon-Gu; Kim, Byung Soo; Park, Moo-Rim; Song, Moo-Kon; Kim, Su-Youn
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- vol. 8, no. 23, pp. 37605 - 37618
- multiple myeloma; aged; bortezomib; drug therapy; combination
- IMPACT JOURNALS LLC
- SCIE; SCOPUS
- Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM. Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS). Thirty-nine (22%) patients were aged >= 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. >= 2; p = 0.0002), beta(2)-microglobulin level (< 5.5 vs. = 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. = 35.1 mg/m(2); p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP. In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients.
- Appears in Collections:
- 의학전문대학원 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.